<DOC>
	<DOCNO>NCT02732327</DOCNO>
	<brief_summary>This study evaluate effect , safety , tolerability ceftazidime-avibactam ( CAZ-AVI ) plus vancomycin linezolid compare standard care plus vancomycin linezolid empiric therapy febrile neutropenic adult cancer .</brief_summary>
	<brief_title>Comparative Study Ceftazidime-Avibactam Versus Standard Care Therapy Febrile Neutropenic Adults With Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<mesh_term>Avibactam</mesh_term>
	<mesh_term>Avibactam , ceftazidime drug combination</mesh_term>
	<mesh_term>Piperacillin , tazobactam drug combination</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Cefepime</mesh_term>
	<criteria>Patients neutropenic fever exist malignancy undergone hematopoietic stem cell transplantation Requires hospitalization intravenous ( IV ) empiric antibiotic therapy Fungal viral infection require additional therapy Known acute viral hepatitis Known human immunodeficiency virus ( HIV ) positive Expected requirement hemodialysis study therapy Received &gt; 24 hour systemic antibacterial therapy within 72 hour initiation inpatient IV study drug Past current history epilepsy seizure disorder Evidence immediately lifethreatening disease , progressively fatal disease , life expectancy 3 month less .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>